The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Alexandra Lynn Medlin, Personal Assistant to British High Commissioner, Cape Town. Ian Adie Murray. For services to education in Murree, Pakistan. Ng Shui-Lai, . For services to welfare, Hong Kong. Edward George Pryor, , Principal Government Town Planner, Hong Kong. Olivia Margaret, Lady Roseveare. For services to education in Malawi Tatica Ernestine Scatliffe. For services to nursing and voluntary work in British Virgin Islands. Leonard Scott, lately Adviser on English Language, European Commission. Josephine Chang Siao Fong-fong. For services to the performing arts, Hong Kong. Neville Maxwell Alexander Smith, lately Chief Immigration Officer, Bermuda. Robert Soto. For services to Scuba diving, British Virgin Islands Edith Margaret Stewart, Matron, Bangkok Nursing Home, Thailand. Heather Themistocleous, Headmistress, Junior (Anglo-Cypriot) School, Nicosia. David Straiten Thomson. For welfare services to the community, Kenya. Valerie Ann Treitlein, Honorary British Consul, Conakry. Carlye Wai-Ling Tsui, . For services to the community, Hong Kong. Valentine Thomas Tudball. For services to the British community in Beirut. Michael Julian Christopher Waters, Deputy Political Adviser, Hong Kong. John Anthony Weaver. For services to the Anglican community, Sliema, Malta. The Reverend Colin Andrew Westmarland. For services to the Church of Scotland, Malta. Henry Winston Willans. For services to the British community, Uruguay. Angela Cheung Wong Wan Yiu, JP. For services to education and hospital administration, Hong Kong. Sister Annie Margaret Wong Kam-lin, Principal, St.
== In popular culture == King Naram-Sin is a character in the 2021 video game House of Ashes, with the main plot occurring in his personal temple. In the game, he is the self-proclaimed "God King" of Akkad, and is engaged in a war with the Gutians after being cursed by the god Enlil; whom he angered after the sacking of his temple. Naram-Sin was voiced and motion captured by Sami Karim. In the 2021 mobile gacha game Blue Archive, Volume F, the innermost chamber of the large floating quantum supercomputer known as the "Ark of Atra-Hasis" (itself a reference to the Akkadian myth) is named "Throne of Naram-Sin".
Eddy was asked to leave the Wentworths' in early 1870. They fell out over several issues, including her request that they pay a printer $600 to publish her Genesis manuscript, which apparently ran to over 100,000 words. After returning to Amesbury to stay with Sally Bagley, she resumed contact with Richard Kennedy, who had been a fellow lodger two years earlier when he was working in a box factory, and had become one of her earliest students; he was 21 and Eddy 49. She now asked him to join her in opening a Moral Science practice in Lynn; he would see patients and she would teach. In June 1870, after agreeing to pay Eddy $1,000 for the previous two years' tuition, Kennedy rented rooms in Lynn and placed a sign in the yard, "Dr. Kennedy". The practice became popular. McClure's wrote that people would say: "Go to Dr. Kennedy. He can't hurt you, even if he doesn't help you."
Walthard cell rests, sometimes called Walthard cell nests, are a benign cluster of epithelial cells most commonly found in the connective tissue of the fallopian tubes, but also seen in the mesovarium, mesosalpinx and ovarian hilus.
== Clinical Significance == Diseases affecting the carnitine shuttle include carnitine palmitoyltransferase I deficiency, carnitine palmitoyltransferase II deficiency, and carnitine-acylcarnitine translocase deficiency, among others. A common symptom among them includes fatigue that presents as an intolerance to physical exertion, with symptoms varying wildly between the main three. Treatment usually consists of dietary supplements, avoidance of fasting and prolonged exercise, and treatment of complications, such as myoglobinuria, hypoglycemia, and hepatic dysfunction. CPT1A has also been investigated as a therapeutic target in cancer. In prostate cancer models, inhibition of CPT1A by the cisplatin prodrug Platin-L suppressed fatty-acid oxidation and increased cellular dependence on glucose.
Sources: en.wikipedia.org
Most of the turquoise deposits in Nevada occur along a wide belt of tectonic activity that coincides with the state's zone of thrust faulting. It strikes at a bearing of about 15° and extends from the northern part of Elko County, southward down to the California border southwest of Tonopah. Nevada has produced a wide diversity of colours and mixes of different matrix patterns, with turquoise from Nevada coming in various shades of blue, blue-green, and green. Some of this unusually-coloured turquoise may contain significant zinc and iron, which is the cause of the beautiful bright green to yellow-green shades. Some of the green to green-yellow shades may actually be variscite or faustite, which are secondary phosphate minerals similar in appearance to turquoise. A significant portion of the Nevada material is also noted for its often attractive brown or black limonite veining, producing what is called "spiderweb matrix". While a number of the Nevada deposits were first worked by Native Americans, the total Nevada turquoise production since the 1870s has been estimated at more than 600 short tons (540 t), including nearly 400 short tons (360 t) from the Carico Lake mine. In spite of increased costs, small scale mining operations continue at a number of turquoise properties in Nevada, including the Godber, Orvil Jack and Carico Lake mines in Lander County, the Pilot Mountain Mine in Mineral County, and several properties in the Royston and Candelaria areas of Esmerelda County.
This defect mobility is the source of most transport phenomena within an ionic crystal, including diffusion and solid state ionic conductivity. When vacancies collide with interstitials (Frenkel), they can recombine and annihilate one another. Similarly, vacancies are removed when they reach the surface of the crystal (Schottky). Defects in the crystal structure generally expand the lattice parameters, reducing the overall density of the crystal. Defects also result in ions in distinctly different local environments, which causes them to experience a different crystal-field symmetry, especially in the case of different cations exchanging lattice sites. This results in a different splitting of d-electron orbitals, so that the optical absorption (and hence colour) can change with defect concentration.
all persons who were members of the Southern Sudan Legislative Assembly; and all South Sudanese who were members of the National Assembly of Sudan, by virtue of their membership in that Assembly. Members of the Council of Ministers who are not members of the National Legislative Assembly must participate in its deliberations but do not have the right to vote. Persons who wish to become members of the National Legislative Assembly must fulfill the eligibility requirements set down by the Constitution for membership of the National Legislature.
==== MeSH D12.776.602.500.500 – oncogene proteins, fusion ==== MeSH D12.776.602.500.500.100 – fusion proteins, bcr-abl MeSH D12.776.602.500.500.320 – fusion proteins, gag-onc MeSH D12.776.602.500.500.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.602.500.500.660 – oncogene protein tpr-met
Sources: en.wikipedia.org
=== Post-surgical recovery === The surgical scars of a breast augmentation mammoplasty develop approximately at 6-weeks post-operative, and fade within months. Depending upon the daily-life physical activities required of the woman, the breast augmentation patient usually resumes her normal life at 1-week post-operative. Moreover, women whose breast implants were emplaced beneath the chest muscles (submuscular placement) usually have a longer, slightly more painful convalescence, because of the healing of the incisions to the chest muscles. Usually, she does not exercise or engage in strenuous physical activities for approximately 6 weeks. During the initial post-operative recovery, the woman is encouraged to regularly exercise (flex and move) her arm to alleviate pain and discomfort; if required, analgesic indwelling medication catheters can alleviate pain Moreover, significantly improved patient recovery has resulted from refined breast-device implantation techniques (submuscular, subglandular) that allow 95 per cent of women to resume their normal lives at 24-hours post-procedure, without bandages, fluid drains, pain pumps, catheters, medical support brassières, or narcotic pain medication.
ADP + a phosphoprotein Thus, the two substrates of this enzyme are ATP and a protein, whereas its two products are ADP and phosphoprotein. The systematic name of this enzyme class is ATP:protein phosphotransferase (non-specific).
=== Chromatography === Alkylamides can be used as chromatographic stationary phases. Those phases have been investigated for the separation of oligonucleotides. Ion-pair reverse-phase high-performance liquid chromatography is used to separate and analyse the oligonucleotides after automated synthesis.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.